Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose

Linh-An C Tuong; Peter Capucilli; Mary Staicu; Allison Ramsey; Edward E Walsh; S Shahzad Mustafa

doi:10.1093/ofid/ofab507

Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose

Open Forum Infect Dis. 2021 Oct 6;8(12):ofab507. doi: 10.1093/ofid/ofab507. eCollection 2021 Dec.

Authors

Linh-An C Tuong¹, Peter Capucilli¹, Mary Staicu², Allison Ramsey^{1

3}, Edward E Walsh⁴, S Shahzad Mustafa^{1

3}

Affiliations

¹ Division of Allergy and Immunology, Rochester Regional Health, Rochester, New York, USA.
² Pharmacy Department, Rochester General Hospital, Rochester, New York, USA.
³ Division of Allergy and Immunology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
⁴ Division of Infectious Diseases, Department of Medicine, University of Rochester and Rochester General Hospital, Rochester, New York, USA.

Abstract

Two mRNA coronavirus disease 2019 (COVID-19) vaccines, Moderna and Pfizer-BioNTech, require 2 doses for maximum efficacy. This case series reports the safety and immunogenicity of a graded administration of the second dose of the Moderna and Pfizer-BioNTech COVID-19 vaccines in patients with immediate hypersensitivity reactions to the first dose.

Keywords: 19; 2 spike protein; COVID; CoV; SARS; graded administration; mRNA vaccine.